National Bank of Canada
LXRX icon

National Bank of Canada’s Lexicon Pharmaceuticals LXRX Stock Holding History

National Bank of Canada’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,205
Closed -$3.46K – 3097
2024
Q3 		$3.46K Buy
2,205
+5
+0.2% +$9 ﹤0.01% 2273
2024
Q2 		$3.66K Hold
2,200
– – ﹤0.01% 2325
2024
Q1 		$3.91K Hold
2,200
– – ﹤0.01% 2355
2023
Q4 		$3.5K Hold
2,200
– – ﹤0.01% 2379
2023
Q3 		$2.22K Hold
2,200
– – ﹤0.01% 2500
2023
Q2 		$5.03K Buy
+2,200
New +$5.84K ﹤0.01% 2339

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

National Bank of Canada's LXRX Position: Q4 2024 in Review

National Bank of Canada sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2024, closing a stake of 2,205 shares — an estimated $3.46K sold.

National Bank of Canada first reported a position in LXRX in Q2 2023 and held it in 6 quarters. The position peaked at $5.03K in Q2 2023. 127 funds tracked by Wall St. Rank hold LXRX as of Q4 2024.

  • National Bank of Canada reported no remaining Lexicon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 2,205 Lexicon Pharmaceuticals shares in Q4 2024, an estimated $3.46K.
  • National Bank of Canada first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • National Bank of Canada's Lexicon Pharmaceuticals position peaked at $5.03K in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.